Market projections show the weight loss drug market is expected to reach $150 billion by 2035, driven by competition among major pharmaceutical companies.
1 report, 1 independent
Updated Jun 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Market projections show the weight loss drug market is expected to reach $150 billion by 2035, driven by competition among major pharmaceutical companies.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.Also in this story
- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.
- Eli Lilly reported compliance status to HRSA and is scheduled to present data at a meeting in Stockholm.
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- Market expectations are shifting toward long-acting injectable technologies, accompanied by partnership terminations affecting drug development rights in the obesity drug sector.
- Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.
- Market pressure due to cost trends is affecting major companies including UnitedHealth Group, Molina Healthcare, Abbott Laboratories, and Eli Lilly, as reported on Investopedia.